FAQs

Where is Cogent Biosciences’ corporate headquarters?
200 CambridgePark Drive, Suite 3100, Cambridge, MA 02140
Where is the company incorporated?
Delaware
When did Cogent Biosciences go public? What was the price?

March 29, 2018; $12.00 / share

What is Cogent Biosciences’ fiscal year?
December 31
Where is Cogent Biosciences stock traded and what is the stock symbol?
Under the symbol UMRX on the NASDAQ. Beginning on October 6, 2020, Cogent will trade on NASDAQ under the ticker symbol “COGT”, and Cogent’s common stock will trade under a new CUSIP number, 19240Q102.
Does Cogent Biosciences pay dividends?
We currently anticipate that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future.
Why were the CVRs issued by Cogent and what is the tax treatment CVRs?

In connection with the Merger, announced on July 6, 2020, Cogent entered into a Contingent Value Rights Agreement, pursuant to which each holder of shares of common stock of record immediately prior to the effective time of the Merger is entitled to one contractual contingent value right ("CVR") for each share of common stock. Each CVR entitles the holder thereof to receive certain common stock and/or cash payments from the net proceeds, if any, related to the disposition of Cogent’s legacy cell therapy assets within three years following the closing of the Merger. The CVRs are not transferable, except in certain limited circumstances as will be provided in the CVR Agreement, will not be certificated or evidenced by any instrument and will not be registered with the SEC or listed for trading on any exchange.

Cogent does not have a material amount of accumulated earnings and profits, and expects no or a small amount of current earnings and profits for the relevant taxable year. Thus, Cogent expects most or all of this distribution would be treated as other than a dividend for U.S. federal income tax purposes.

As per the CVR Agreement, after Cogent has a disposition of any of Cogent’s legacy cell therapy assets, stock payments relating to the CVRs are expected to be issued approximately fifty-five (55) days following the end of each calendar quarter that ends on or prior to December 31, 2020, and cash payments relating to the CVRs are expected to be issued approximately fifty-five (55) days following the end of each calendar quarter that ends on or following March 31, 2021.

PLEASE CONSULT YOUR TAX ADVISOR WITH RESPECT TO THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER AND THE ISSUANCE OF THE CVRS IN LIGHT OF YOUR PERSONAL CIRCUMSTANCES AND THE PROPER CHARACTERIZATION OF THE RECEIPT OF THE CVRs.

Who is Cogent Biosciences’ transfer agent and how do I contact the transfer agent with questions about my stock?

Computershare customer service can be accessed online at:

www-us.computershare.com/investor/Contact/Enquiry

How do I transfer stock, change the address on my shareholder account, or replace a lost stock certificate?

Any questions regarding name or address changes or stock certificates should be addressed to Computershare at www-us.computershare.com/investor/Contact/Enquiry

Does Cogent Biosciences have a direct stock purchase plan?
No.
Who is Cogent Biosciences’ auditor?
PricewaterhouseCoopers
Who is Cogent Biosciences’ legal counsel?
Goodwin Law
Where can I find out more information about Cogent Biosciences?
Our website is located at www.cogentbio.com. The investors’ section is investors.cogentbio.com,  and it contains all the latest press releases and SEC filings.
How can I obtain further information or materials on Cogent Biosciences?
For general inquiries, please contact info@unumrx.com.
For partnership opportunities, please contact  partnering@unumrx.com.
For media requests, please contact communications@unurmx.com.
 
How can I receive email updates about Cogent?
Please sign up for email alerts using the button at the bottom of the page.
Whom should I contact regarding investor inquiries?

Investor inquiries should be directed to

Chuck Wilson, CEO
Chuck.wilson@unumrx.com